Outlook Aims To Reverse US FDA’s Rejection Of Bevacizumab For AMD

Low On Cash, Rush Is On To Clarify Agency’s Concerns

 
• By Mandy Jackson

Outlook Therapeutics received a complete response letter citing manufacturing issues and seeking more data for Lytenava (ONS-5010), its bevacizumab injection for wet age-related macular degeneration.

Close up cropped shot, face of senior woman eye looking straight, into distance.
Outlook will request at Type A meeting with the FDA to discuss the CRL • Source: Shutterstock

More from New Products

More from Scrip